News
Latest News, Announcements, and Press Releases
25Feb 20
Codexis to Present at Two Investment Conferences in March
REDWOOD CITY, Calif. , Feb. 25, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: Cowen and Company 40 th Annual Health Care Conference on Tuesday,…
read more20Feb 20
Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27
REDWOOD CITY, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, February 27, 2020…
read more13Jan 20
Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing
CHONGQING, China , Jan. 13, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (SZSE: 300363) fermentation pilot laboratory located in Porton’s Changshou site, achieving another important…
read more10Jan 20
Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement
REDWOOD CITY, Calif. , Jan. 10, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have signed…
read more23Dec 19
Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing
REDWOOD CITY, Calif. , Dec. 23, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4 TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed…
read more05Dec 19
Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir
REDWOOD CITY, Calif. , Dec. 05, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the publication with Merck , known as MSD outside the United States and Canada , of a paper in the…
read more05Nov 19
Codexis Reports Third Quarter 2019 Financial Results
Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver ® licensing revenues Eleven customers each contributed at least a quarter million dollars in revenue Conference call begins at 4:30 pm Eastern time today REDWOOD…
read more05Nov 19
Codexis to Participate in Four Investment Conferences in November
REDWOOD CITY, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming investment conferences: 10 th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12,…
read more29Oct 19
Codexis to Hold Third Quarter 2019 Conference Call on November 5
REDWOOD CITY, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results after market close on Tuesday, November 5, 2019 . Codexis management…
read more15Oct 19
Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field
Industry and academic leaders convened to discuss the direction of protein engineering for a wide range of applications REDWOOD CITY, Calif. , Oct. 15, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, assembled approximately 150…
read moreSince 2002, Codexis has created new technologies to unlock the power of proteins®. Put our unmatched protein engineering expertise to work for you.
Unlock the power of proteins® with Codexis
Learn More
Company
Industries